The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Gemtuzumab Ozogamicin in Children and Adolescents With De Novo Acute Myeloid Leukemia Improves Event-Free Survival by Reducing Relapse Risk: Results From the Randomized Phase III Children's Oncology Group Trial AAML0531
Open accessAbstract
Purpose: To improve survival rates in children with acute myeloid leukemia (AML), we evaluated gemtuzumab-ozogamicin (GO), a humanized immunoconjugate targeted against CD33, as an alternative to further chemotherapy dose escalation. Our primary objective was to determine whether adding GO to standard chemotherapy improved event-free survival (EFS) and overall survival (OS) in children with newly diagnosed AML. Our secondary objectives examined outcomes by risk group and method of intensification. Patients and Methods: Children, adolescents, and young adults ages 0 to 29 years with newly diagnosed AML were enrolled onto Children's Oncology Group trial AAML0531 and then were randomly assigned to either standard five-course chemotherapy alone or to the same chemotherapy with two doses of GO (3 mg/m 2 /dose) administered once in induction course 1 and once in intensification course 2 (two of three). Results: There were 1,022 evaluable patients enrolled. GO significantly improved EFS (3 years: 53.1% v 46.9%; hazard ratio [HzR], 0.83; 95% CI, 0.70 to 0.99; P = .04) but not OS (3 years: 69.4% v 65.4%; HzR, 0.91; 95% CI, 0.74 to 1.13; P = .39). Although remission was not improved (88% v 85%; P = .15), posthoc analyses found relapse risk (RR) was significantly reduced among GO recipients overall (3 years: 32.8% v 41.3%; HzR, 0.73; 95% CI, 0.58 to 0.91; P = .006). Despite an increased postremission toxic mortality (3 years: 6.6% v 4.1%; HzR, 1.69; 95% CI, 0.93 to 3.08; P = .09), disease-free survival was better among GO recipients (3 years: 60.6% v 54.7%; HzR, 0.82; 95% CI, 0.67 to 1.02; P = .07). Conclusion: GO added to chemotherapy improved EFS through a reduction in RR for children and adolescents with AML.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Regression Models and Life-Tables
Cox, D. R. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_37 · Cited by 26,297
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
The Statistical Analysis of Failure Time Data.
Aitkin, M., Kalbfleisch, J. D., & Prentice, R. L. (1981) · Biometrics · doi:10.2307/2530581 · Cited by 9,877
The World Health Organization (WHO) classification of the myeloid neoplasms
Vardiman, J. W., Harris, N. L., & Brunning, R. D. (2002) · Blood · doi:10.1182/blood-2002-04-1199 · Cited by 2,197
Kottaridis, P. D., Gale, R. E., Frew, M. E., Harrison, G., Langabeer, S. E., Belton, A. A., Walker, H., Wheatley, K., Bowen, D. T., Burnett, A. K., et al. (2001) · Blood · doi:10.1182/blood.v98.6.1752 · Cited by 1,551
Outcomes for children and adolescents with cancer: challenges for the twenty-first century
Smith, M. A., Seibel, N. L., Altekruse, S. F., Ries, L. A. G., Melbert, D. L., O'Leary, M., Smith, F. O., & Reaman, G. H. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.0421 · Cited by 1,026 · cited 1×
“INTRODUCTION Acute myeloid leukemia (AML) is among the most difficult to treat of the childhood cancers because of its disease heterogeneity, high relapse, and toxic mortality.(1,2) Therapeutic advances have included chemotherapy intensification and adding allogeneic stem-cell transplantation (SCT).”
BackgroundSelf-citationCastaigne, S., Pautas, C., Terré, C., Raffoux, E., Bordessoule, D., Bastie, J.-N., Legrand, O., Thomas, X., Turlure, P., Reman, O., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60485-1 · Cited by 1,015
Anthracycline Dose Intensification in Acute Myeloid Leukemia
Fernandez, H. F., Sun, Z., Yao, X., Litzow, M. R., Luger, S. M., Paietta, E. M., Racevskis, J., Dewald, G. W., Ketterling, R. P., Bennett, J. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0904544 · Cited by 919
Sievers, E. L., Larson, R. A., Stadtmauer, E. A., Estey, E., Löwenberg, B., Dombret, H., Karanes, C., Theobald, M., Bennett, J. M., Sherman, M. L., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.13.3244 · Cited by 899
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
High-Dose Daunorubicin in Older Patients with Acute Myeloid Leukemia
Löwenberg, B., Ossenkoppele, G. J., van Putten, W., Schouten, H. C., Graux, C., Ferrant, A., Sonneveld, P., Maertens, J., Jongen-Lavrencic, M., von Lilienfeld-Toal, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901409 · Cited by 828
Burnett, A. K., Hills, R. K., Milligan, D., Kjeldsen, L., Kell, J., Russell, N. H., Yin, J. A. L., Hunter, A., Goldstone, A. H., & Wheatley, K. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.31.4310 · Cited by 657
Petersdorf, S. H., Kopecky, K. J., Slovak, M., Willman, C., Nevill, T., Brandwein, J., Larson, R. A., Erba, H. P., Stiff, P. J., Stuart, R. K., et al. (2013) · Blood · doi:10.1182/blood-2013-01-466706 · Cited by 638
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Self-citationWheatley, K., Burnett, A. K., Goldstone, A. H., Gray, R. G., Hann, I. M., Harrison, C. J., Rees, J. K. H., Stevens, R. F., & Walker, H. (1999) · British Journal of Haematology · doi:10.1046/j.1365-2141.1999.01684.x · Cited by 434
Burnett, A. K., Russell, N. H., Hills, R. K., Kell, J., Freeman, S., Kjeldsen, L., Hunter, A. E., Yin, J., Craddock, C. F., Dufva, I. H., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.2964 · Cited by 409
Clinical implications of FLT3 mutations in pediatric AML
Meshinchi, S., Alonzo, T. A., Stirewalt, D. L., Zwaan, M., Zimmerman, M., Reinhardt, D., Kaspers, G. J. L., Heerema, N. A., Gerbing, R., Lange, B. J., et al. (2006) · Blood · doi:10.1182/blood-2006-03-009233 · Cited by 395
Self-citationKung Sutherland, M. S., Walter, R. B., Jeffrey, S. C., Burke, P. J., Yu, C., Kostner, H., Stone, I., Ryan, M. C., Sussman, D., Lyon, R. P., et al. (2013) · Blood · doi:10.1182/blood-2013-03-491506 · Cited by 391
Walter, R. B., Buckley, S. A., Pagel, J. M., Wood, B. L., Storer, B. E., Sandmaier, B. M., Fang, M., Gyurkocza, B., Delaney, C., Radich, J. P., et al. (2013) · Blood · doi:10.1182/blood-2013-06-506725 · Cited by 360
Ricart, A. D. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0486 · Cited by 332
Woods, W., Kobrinsky, N., Buckley, J., Lee, J., Sanders, J., Neudorf, S., Gold, S., Barnard, D., DeSwarte, J., Dusenbery, K., et al. (1996) · Blood · doi:10.1182/blood.v87.12.4979.bloodjournal87124979 · Cited by 329
Wadleigh, M., Richardson, P. G., Zahrieh, D., Lee, S. J., Cutler, C., Ho, V., Alyea, E. P., Antin, J. H., Stone, R. M., Soiffer, R. J., et al. (2003) · Blood · doi:10.1182/blood-2003-01-0255 · Cited by 323
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Walter, R. B., Appelbaum, F. R., Estey, E. H., & Bernstein, I. D. (2012) · Blood · doi:10.1182/blood-2011-11-325050 · Cited by 321
Stevens, R. F., Hann, I. M., Wheatley, K., Gray, R. G., & Party, O. B. O. T. M. C. L. W. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00677.x · Cited by 309
Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials
Gibson, B. E. S., Wheatley, K., Hann, I. M., Stevens, R. F., Webb, D., Hills, R. K., De Graaf, S. S. N., Harrison, C. J., & for the United Kingdom Childhood Leukaemia Working Party, A. T. D. C. O. G. (2005) · Leukemia · doi:10.1038/sj.leu.2403924 · Cited by 303
Lange, B. J., Smith, F. O., Feusner, J., Barnard, D. R., Dinndorf, P., Feig, S., Heerema, N. A., Arndt, C., Arceci, R. J., Seibel, N., et al. (2008) · Blood · doi:10.1182/blood-2007-04-084293 · Cited by 274
Self-citationThe myth of the second remission of acute leukemia in the adult
Forman, S. J., & Rowe, J. M. (2013) · Blood · doi:10.1182/blood-2012-08-234492 · Cited by 225
Burnett, A. K., Goldstone, A., Hills, R. K., Milligan, D., Prentice, A., Yin, J., Wheatley, K., Hunter, A., & Russell, N. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.5977 · Cited by 207
Cooper, T. M., Franklin, J., Gerbing, R. B., Alonzo, T. A., Hurwitz, C., Raimondi, S. C., Hirsch, B., Smith, F. O., Mathew, P., Arceci, R. J., et al. (2012) · Cancer · doi:10.1002/cncr.26190 · Cited by 199
Self-citationGemtuzumab ozogamicin in acute myeloid leukemia: a remarkable saga about an active drug
Rowe, J. M., & Löwenberg, B. (2013) · Blood · doi:10.1182/blood-2013-03-490482 · Cited by 143
van der Velden, V. H. J., Boeckx, N., Jedema, I., Marvelde, J. G. T., Hoogeveen, P. G., Boogaerts, M. A., & van Dongen, J. J. M. (2004) · Leukemia · doi:10.1038/sj.leu.2403350 · Cited by 119
Zwaan, C. M. (2003) · Blood · doi:10.1182/blood-2002-07-1947 · Cited by 101
Aplenc, R., Alonzo, T. A., Gerbing, R. B., Lange, B. J., Hurwitz, C. A., Wells, R. J., Bernstein, I. D., Buckley, P. J., Krimmel, K., Smith, F. O., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.0096 · Cited by 92
Self-citationChildren's Oncology Group's 2013 blueprint for research: Acute myeloid leukemia
Gamis, A. S., Alonzo, T. A., Perentesis, J. P., & Meshinchi, S. (2012) · Pediatric Blood & Cancer · doi:10.1002/pbc.24432 · Cited by 85
Self-citationCD33 as a Target for Selective Ablation of Acute Myeloid Leukemia
Bernstein, I. D. (2002) · Clinical Lymphoma · doi:10.3816/clm.2002.s.002 · Cited by 44
Chevallier, P., Roland, V., Mahé, B., Juge‐Morineau, N., Dubruille, V., Guillaume, T., Vigouroux, S., Moreau, P., Milpied, N. J., Garand, R., et al. (2005) · Leukemia Research · doi:10.1016/j.leukres.2005.02.005 · Cited by 37
Horan, J., Meshinchi, S., Loken, M. R., Alonzo, T. A., Aplenc, R., Davies, S. M., Gerbing, R. B., & Gamis, A. S. (2013) · Blood · doi:10.1182/blood.v122.21.65.65 · Cited by 3
Self-citation
Cited by
Cancer stem cells—Origins and biomarkers: Perspectives for targeted personalized therapies
Walcher, L., Kistenmacher, A.-K., Suo, H., Kitte, R., Dluczek, S., Strauß, A., Blaudszun, A.-R., Yevsa, T., Fricke, S., & Kossatz-Boehlert, U. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01280 · Cited by 1,007
Bolouri, H., Farrar, J. E., Triche, T., Ries, R. E., Lim, E. L., Alonzo, T. A., Ma, Y., Moore, R., Mungall, A. J., Marra, M. A., et al. (2018) · Nature Medicine · doi:10.1038/nm.4439 · Cited by 848
Self-citationShort, N. J., Rytting, M. E., & Cortes, J. E. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31041-9 · Cited by 781
Hills, R. K., Castaigne, S., Appelbaum, F. R., Delaunay, J., Petersdorf, S., Othus, M., Estey, E. H., Dombret, H., Chevret, S., Ifrah, N., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70281-5 · Cited by 721
Khwaja, A., Bjorkholm, M., Gale, R. E., Levine, R. L., Jordan, C. T., Ehninger, G., Bloomfield, C. D., Estey, E., Burnett, A., Cornelissen, J. J., et al. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.10 · Cited by 592
Metadata
- Authors
- Gamis, A. S., Alonzo, T. A., Meshinchi, S., Sung, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Kahwash, S. B., Heerema-McKenney, A., Winter, L., Glick, K., Davies, S. M., Byron, P., Smith, F. O., & Aplenc, R.
- Venue
- Journal of Clinical Oncology
- Published
- 2014-09-20
- Volume
- 32
- Issue
- 27
- Pages
- 3021-3032
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2169923083
- Cited by
- 486
- References
- 41
- FWCI
- 22.65
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.